GST Council's Upcoming Decision: Impact on Pharma's Input Tax Credit for Free Samples

GST Relief for Pharma Samples May Be on the Horizon—But with Tight Conditions

The pharma industry is holding its breath right now. A key decision from the GST Council could be around the corner—one that might finally untangle the mess around Input Tax Credit (ITC) on free drug samples. If you’ve ever worked in or around the pharma sector, you know this has been a sore spot for years.

So, what’s the issue?

Currently, the law says you can’t claim ITC on free samples. That’s thanks to Section 17(5) of the CGST Act, 2017, which basically tells businesses: if you give something away for free—whether it’s a gift or a sample—you can’t claim a credit for the GST you paid to make or buy it. For pharma companies, this has been a long-standing pain point. After all, these aren’t chocolates or keychains being handed out—they’re prescription drugs, often given out in tiny batches to licensed professionals for therapeutic evaluation.

Why is the industry pushing back?

Let’s be clear—pharma companies aren’t handing out these samples for fun. Here’s what they say:

It’s a professional tool, not a gift: These samples are meant for qualified doctors and hospitals so that they can test a product before it’s prescribed to patients. In many cases, doctors actually need to evaluate new drugs this way before introducing them into their practice.

It’s often a regulatory requirement: Whether it's industry codes of conduct or government-issued advisories, free sampling of drugs is a recognised part of how the industry ensures patient safety.

It adds up financially: For some manufacturers, free samples can make up nearly 2% of their total production cost. And in a sector where prices are tightly controlled, losing ITC on this can sting.

It strains cash flow: When companies can’t claim that input tax, it ties up working capital—capital that could’ve been better used for R&D or for expanding access to essential medicines.

Pharma companies are essentially arguing: “We’re not marketing; we’re complying. This isn’t gifting. It’s part of how we do regulated business.” And they’re asking the Council to treat them differently than, say, a brand giving away free merchandise.

What’s likely to change?

The GST Council is now reportedly weighing a proposal that could shift the game. While there’s no official word yet, here’s what insiders think may be in the works:

{Input Tax Credit on free samples} – but only in specific cases:

There could be a targeted carve-out in the law allowing ITC only when the free sample is:

A regulated pharma product
Given in the course of professional practice
Distributed under documented, verifiable circumstances

In other words: this isn’t about opening the door to every business handing out freebies—just about recognising that free samples in pharma have a different purpose.

Safety and Compliance Restrictions:

If the Council does give relief, it likely won’t be a blanket exemption. Instead, some of the expected guardrails could include:

Only for Schedule H drugs (i.e., prescription-only medicines)
Limits on the quantity and value of samples eligible for ITC
Strict documentation, showing why each sample was given, and to whom

Think digital audit trails, mandatory reporting formats, maybe even declarations through pharma codes or industry bodies.

Paperwork Will Be Key

Don’t expect a free ride. If the Council moves ahead, companies will likely be asked to keep more detailed records, maybe even file supplementary reports. The idea is to offer relief for genuine pharmaceutical use while preventing misuse of the rule in other industries.

Pharma’s Mood: Hopeful, But Cautious

Ask any pharma tax professional and you’ll hear the same thing: they’re hoping for clarity, but they’re also preparing for conditions. Some are already tightening their internal documentation and revisiting SOPs, anticipating that compliance could become more layered. As one advisor put it, a fair circular “could unlock significant ITC currently mired in litigation.”

A clear directive would also reduce unnecessary tax disputes and litigation over what qualifies as a “gift” versus a “professional sample”—a grey area that’s caused more than a few courtroom headaches.

What’s Next?

The Council hasn’t officially released anything yet, but pharma companies are watching the next GST Council meeting like hawks. If a clarification or circular is issued, it would be one of the biggest sector-specific GST reliefs since the system was rolled out in 2017.

So, if you're in the pharma space, now is the time to get your paperwork in order. Even if the rules change in your favour, the relief will almost certainly come with strings attached.

Until the Council acts, nothing is certain. But if the change comes through, it could ease working capital stress, reduce compliance risk, and bring long-overdue recognition to a crucial business practice.